Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Clinical Pharmacology in Drug Development|June 10, 2017
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega-3-Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single-Blind, Randomized, Placebo-Controlled TrialYoshinori Noda, Catarina Nilsson, Hitoshi Shimada, et al.Virulence|February 2, 2011
Modeling gene associations for virulence classification of verocytotoxin-producing E. coli (VTEC) from patients and beefTom Andersson, Catarina Nilsson, Eva Kjellin, et al.Pharmaceutical Research|August 19, 2010
Predicting intestinal precipitation--a case example for a basic BCS class II drugSara Carlert, Anna Pålsson, Gunilla Hanisch, et al.Lipids in Health and Disease|June 1, 2020
Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover studyRichard L Dunbar, Daniel Gaudet, Michael Davidson, et al.CPT: Pharmacometrics & Systems Pharmacology|August 5, 2025
A Case Study of Model-Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3Jane Knöchel, Catarina Nilsson, Björn Carlsson, et al.Journal of Lipid Research|July 12, 2019
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemiaVictor Sokolov, Gabriel Helmlinger, Catarina Nilsson, et al.British Journal of Clinical Pharmacology|March 20, 2024
Population pharmacokinetics of a novel PCSK9 antisense oligonucleotideOskar Clewe, Dinko Rekić, Angelica L Quartino, et al.British Journal of Clinical Pharmacology|June 2, 2022
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT intervalDinko Rekić, Ivan Azarov, Jane Knöchel, et al.CPT: Pharmacometrics & Systems Pharmacology|September 20, 2022
A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase IIJane Knöchel, Catarina Nilsson, Björn Carlsson, et al.Blood Advances|January 9, 2026
RNA interference therapy targeting coagulation factor XI - a first-in-human trial of RBD4059Anders Gabrielsen, Sebastian Ueckert, Catarina Nilsson, et al.Pageof 3